Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has secured firm commitments for a share placement of approximately A$12 million at A$0.042 per share, issuing about 285.7 million new shares, with directors including CEO Dr Steven Gourlay committing around A$667,000 subject to shareholder approval. The funds, alongside up to A$5 million to be sought via a share purchase plan for eligible shareholders on the same terms, extend the company’s funding beyond the expected November 2026 topline results of its XanaMIA pivotal Alzheimer’s trial, de‑risking the program’s near-term development, broadening institutional and retail investor participation, and supporting the open-label extension and general corporate purposes.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing therapies for neurological conditions, with a particular emphasis on Alzheimer’s disease. Its lead program is the XanaMIA pivotal phase 2b/3 clinical trial targeting Alzheimer’s, positioning the company within the clinical-stage biopharmaceutical sector addressing unmet needs in neurodegenerative disorders.
YTD Price Performance: -26.23%
Average Trading Volume: 5,840,451
Technical Sentiment Signal: Hold
Current Market Cap: A$143.6M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.